SHIRE PLC: Angus Russell to retire in 2013

Dublin, Ireland - October 25, 2012 - The Board of Directors of Shire (LSE: SHP,
NASDAQ: SHPG), announces the retirement in 2013 of Chief Executive Angus
Russell after 13 years with the Company and 32 years in the pharmaceutical
Flemming Ornskov MD, MBA, MPH will join the Shire Board as Chief Executive
Designate on January 2, 2013 following completion of his notice period with his
current employer. 
There will then be a handover period of several months to ensure a smooth
transition before Flemming becomes CEO on April 30, 2013; the date of the Shire
Annual General Meeting. As Chief Executive Designate, Flemming will spend time
with all three Shire businesses and will have a special focus initially on the
Specialty Pharmaceuticals business. He will be based at Shire's offices outside
Philadelphia, USA, during this period. 
Flemming joins from Bayer where, as Chief Marketing Officer and Global Head,
Strategic Marketing for General and Specialty Medicine he oversees the full
pharmaceutical product portfolio, with sales in excess of 10 billion Euros from
global marketing units in Europe, China and the US. 
Flemming Ornskov said: 
"Shire stands out in the industry. I'm motivated and inspired by the Company's
vision and excited to bring the combination of my medical, multi-national and
entrepreneurial business background to lead Shire to the next phase of its
Shire Chairman Matthew Emmens said: 
"Flemming is highly qualified for this role and brings diverse and deep
expertise to Shire. His pharmaceutical experience spans start-ups, equity and
venture capital as well as mature global multi-nationals, in marketing roles
and increasingly senior leadership positions. He's lived and worked in both
Europe and the United States and had responsibility for businesses across Asia.
As an MD with most of his training in pediatrics, he brings important insight
and understanding of patients needs. This unique combination of skills and
experience will bring an innovative outlook to Shire and help steer the Company
toward continued growth." 
"The Board would like to thank Angus for his excellent leadership and
impressive contributions over many years during which time Shire has grown to
become an industry leading global company. Shire has a distinctive business
model and is financially strong and has consistently executed on its growth
strategy. Angus led the Company through a period of extraordinary growth and
was instrumental in establishing a winning strategy and a powerful and
compelling culture. We wish him and his family well in his retirement" 
Angus Russell said: 
"I've enjoyed every day of my time at Shire. I'm very pleased to have been a
part of the growth story of this excellent company and to be leaving it in such
great shape for further success. I'm delighted to hand the leadership over to
such a talented and visionary individual. I'll continue to watch the progress
of this outstanding organisation in the years ahead." 
Further background on Flemming Ornskov 
2010- present: Bayer Chief Marketing Officer and Global Head, Strategic
Marketing for General & Specialty Medicine (Berlin, Germany). 
2008-10: Global President, Pharmaceuticals and OTC Bausch & Lomb Inc (Rochester
2006-8: Lifecycle Pharma A/S (Denmark) Chairman of the Board of Directors and
stepped in as CEO to take the company through an IPO. 
2005-6: President and CEO of Ikaria Inc a privately owned biotech company in
Seattle, USA, a majority stake of which was sold to a private equity firm. The
company was then merged with Ino Therapeutics Inc. 
Earlier in his pharmaceutical career he had roles of increasing responsibility
at Merck & Co Inc and Novartis (where he first headed the US Cardiovascular and
later the Global Ophthalmic Franchises and was a member of the Pharmaceutical
Executive Committee), following a distinguished period in hospital and academic
Flemming qualified as a Doctor of Medicine at the University of Copenhagen
Medical School and gained an MPH at Harvard University School of Public Health,
Boston. His early medical and academic career included roles in internal
medicine, emergency medicine and pediatrics, as well as clinical decision
sciences at medical schools and hospitals in Denmark and France. 
He gained an MBA from the INSEAD business school in Fontainebleau, France. 
He currently serves as non executive Chairman of the Board of Directors for
biotechnology companies Santaris Pharma A/S and Evotec AG and is on the Board
of Directors for PCI Biotech Holding ASA. 
Fluent in four languages (Danish, English, French and German), Flemming is
married with four children. 
The search process 
Shire began its search for a new President for its Specialty Pharmaceuticals
business in April and in conducting this, sought a candidate who would, in due
course, be a potential successor for the CEO. A thorough process was led by
Chairman Matthew Emmens and the Shire Nomination Committee. Support was
provided by an external search firm. 
There is no further information that is required to be disclosed under 9.6.13R
of the UK Listing Rules. 
For further information please contact: 
Investor Relations                                                              
Eric Rojas                         +1 781 482 0999    
Sarah Elton-Farr               +44 1256 894157    
Jessica Mann                        +44 1256 894 280   
Gwen Fisher                       +1 484 595 9836    
Jessica Cotrone                  +1 781 482 9538    
Notes to editors 
Shire enables people with life-altering conditions to lead better lives. 
Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of: 
* Behavioral Health and Gastro Intestinal conditions 

      * Rare Diseases
      * Regenerative Medicine
    as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.


Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks or
uncertainties materialize, the Company's results could be materially adversely
affected. The risks and uncertainties include, but are not limited to, risks
associated with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company's Specialty
Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as
well as the ability to secure new products for commercialization and/or
development; government regulation of the Company's products; the Company's
ability to manufacture its products in sufficient quantities to meet demand;
the impact of competitive therapies on the Company's products; the Company's
ability to register, maintain and enforce patents and other intellectual
property rights relating to its products; the Company's ability to obtain and
maintain government and other third-party reimbursement for its products; and
other risks and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
-0- Oct/25/2012 11:01 GMT
Press spacebar to pause and continue. Press esc to stop.